Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Integrated Drug Discovery

The rapid and efficient feedback of key assay data into the iterative design and synthesis of putative drug molecules is a critical success factor in the timely delivery of drug candidates.

Whilst many large organisations strive to break down silo mentalities that segment disciplines and create barriers to team-based problem solving, Sygnature has, from day one, adopted a highly collaborative and adaptable team structure.  As an integrated CRO, our teams are co-located in mixed discipline labs to facilitate effective communication and problem solving; allowing us to respond quickly to the changing needs of each research project.

Communication with clients and their authorised consultants is facilitated by our excellent informatics platform to enable transparent discussion and review or revision of project strategies.

Sygnature has successfully recruited many industry experienced scientists from across the globe to enrich and augment the drug-hunting knowledge-base of our founding scientists. Our scientific teams are invariably highly qualified and each program is allocated a project leader with relevant drug discovery experience and all are keen to collaborate with clients to achieve their shared goals.  Their intellectual contribution is highly valued by our clients and recognised by co-authorship in numerous published patents assigned to and held by our client companies.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

Integrated Drug Discovery Services

Target Validation

Sygnature provides a wide range of biochemical, biophysical and cell biology methodologies for target validation, target engagement and mode of action determination.


Hit Identification

Sygnature is able to provide hit identification via screening services in a number of modes including fragment screening, virtual screening, phenotypic, high content and high throughput screening.



Sygnature is a premium provider of Hit to Lead services using its extensive expertise to assess screening hits and select the most suitable chemical series to develop into drug leads.


Lead Optimisation

Sygnature’s highly efficient Lead Optimisation services are facilitated by the rapid generation of key in-vitro data to enable our scientists to design potent molecules with drug-like properties.


Fragment-Based Drug Discovery

Screening of our proprietary fragment library will provide low molecular weight hits that can be grown in a structure guided manner to deliver potent ligands with drug-like properties.


Structure-Based Drug Discovery

Whatever the origin of the hits, a structure-based approach can accelerate the enhancement of selectivity and potency during a multi-parameter lead optimisation process.



We offer multi-disciplinary teams with the drug discovery expertise and the collaborative approach that is needed to drive to a successful conclusion on your research project.


Latest News

View All

Sygnature assists New York Medical College in…

Sygnature Discovery expands SPR capacity

Sygnature Discovery announces collaboration with software firm…

Pathios Therapeutics and Sygnature Discovery sign strategic…